Published in PLoS One on October 16, 2015
Acute liver injury in a Glatopa-treated patient with MS. Neurol Neuroimmunol Neuroinflamm (2017) 0.75
Biomaterials Strategies for Generating Therapeutic Immune Responses. Adv Drug Deliv Rev (2017) 0.75
Exploration, normalization, and summaries of high density oligonucleotide array probe level data. Biostatistics (2003) 100.88
Statistical significance for genomewide studies. Proc Natl Acad Sci U S A (2003) 88.64
A comparison of normalization methods for high density oligonucleotide array data based on variance and bias. Bioinformatics (2003) 82.89
Flexible programs of chemokine receptor expression on human polarized T helper 1 and 2 lymphocytes. J Exp Med (1998) 7.24
What is principal component analysis? Nat Biotechnol (2008) 5.28
Rules of chemokine receptor association with T cell polarization in vivo. J Clin Invest (2001) 2.87
Transcriptional regulation of Th1/Th2 polarization. Immunol Today (2000) 2.39
Microarrays: the use of oligonucleotides and cDNA for the analysis of gene expression. Drug Discov Today (2003) 2.08
Copolymer 1 induces T cells of the T helper type 2 that crossreact with myelin basic protein and suppress experimental autoimmune encephalomyelitis. Proc Natl Acad Sci U S A (1997) 2.00
Glatiramer acetate (Copaxone) induces degenerate, Th2-polarized immune responses in patients with multiple sclerosis. J Clin Invest (2000) 2.00
Multiple sclerosis: comparison of copolymer-1- reactive T cell lines from treated and untreated subjects reveals cytokine shift from T helper 1 to T helper 2 cells. Proc Natl Acad Sci U S A (2000) 1.53
The Ets transcription factor ERM is Th1-specific and induced by IL-12 through a Stat4-dependent pathway. Proc Natl Acad Sci U S A (1999) 1.33
Mechanisms of action of glatiramer acetate in multiple sclerosis. Neurology (2001) 1.30
Glatiramer acetate (copolymer-1, copaxone) promotes Th2 cell development and increased IL-10 production through modulation of dendritic cells. J Immunol (2003) 1.30
Treatment of multiple sclerosis with copolymer-1 (Copaxone): implicating mechanisms of Th1 to Th2/Th3 immune-deviation. J Neuroimmunol (1998) 1.20
Comparing the biological impact of glatiramer acetate with the biological impact of a generic. PLoS One (2014) 1.17
Mechanism of action of glatiramer acetate in multiple sclerosis and its potential for the development of new applications. Proc Natl Acad Sci U S A (2004) 1.17
Glatiramer acetate in the treatment of multiple sclerosis: emerging concepts regarding its mechanism of action. CNS Drugs (2011) 1.15
The mechanism of action of glatiramer acetate treatment in multiple sclerosis. Neurology (2010) 1.10
Treatment of multiple sclerosis with Copaxone (COP): Elispot assay detects COP-induced interleukin-4 and interferon-gamma response in blood cells. Brain (2001) 1.03
Demyelination arrest and remyelination induced by glatiramer acetate treatment of experimental autoimmune encephalomyelitis. Proc Natl Acad Sci U S A (2008) 1.03
Promoting oligodendrogenesis and myelin repair using the multiple sclerosis medication glatiramer acetate. Proc Natl Acad Sci U S A (2009) 1.02
Modulation of chemokine receptor expression and chemotactic responsiveness during differentiation of human naive T cells into Th1 or Th2 cells. Eur J Immunol (2002) 0.97
Gene expression analysis reveals functional pathways of glatiramer acetate activation. Expert Opin Ther Targets (2013) 0.96